LYEL | Lyell Immunopharma, Inc. | [NASD]
Index- P/E- EPS (ttm)-0.73 Insider Own3.10% Shs Outstand249.59M Perf Week-4.50%
Market Cap677.00M Forward P/E- EPS next Y-1.37 Insider Trans0.00% Shs Float210.08M Perf Month35.96%
Income-181.90M PEG- EPS next Q-0.27 Inst Own66.00% Short Float / Ratio9.97% / 20.30 Perf Quarter28.37%
Sales84.20M P/S8.04 EPS this Y28.80% Inst Trans4.40% Short Interest20.95M Perf Half Y-33.65%
Book/sh3.14 P/B0.88 EPS next Y-19.10% ROA-19.10% Target Price7.25 Perf Year-32.52%
Cash/sh2.50 P/C1.10 EPS next 5Y-7.90% ROE-22.00% 52W Range1.77 - 8.74 Perf YTD-20.46%
Dividend- P/FCF- EPS past 5Y- ROI-23.00% 52W High-68.42% Beta-
Dividend %- Quick Ratio20.30 Sales past 5Y- Gross Margin- 52W Low55.93% ATR0.24
Employees274 Current Ratio20.30 Sales Q/Q-83.30% Oper. Margin- RSI (14)54.78 Volatility7.52% 9.66%
OptionableYes Debt/Eq0.00 EPS Q/Q3.90% Profit Margin- Rel Volume0.62 Prev Close2.89
ShortableYes LT Debt/Eq0.00 EarningsMay 04 AMC Payout- Avg Volume1.03M Price2.76
Recom2.20 SMA206.35% SMA5013.80% SMA200-33.96% Volume647,755 Change-4.50%
Date Action Analyst Rating Change Price Target Change
Nov-14-22Downgrade Morgan Stanley Overweight → Equal-Weight $15 → $7
Nov-11-22Downgrade Goldman Buy → Neutral $13 → $7
Oct-17-22Initiated H.C. Wainwright Buy $12
Jul-12-21Initiated Morgan Stanley Overweight $25
Jul-12-21Initiated JP Morgan Overweight $22
Jul-12-21Initiated Goldman Buy $30
Jul-12-21Initiated BofA Securities Buy $25
May-04-23 07:25PM
May-02-23 04:05PM
Apr-17-23 07:11AM
Mar-27-23 04:52AM
10:14AM Loading…
Mar-26-23 10:14AM
Feb-28-23 08:15PM
Feb-02-23 06:43AM
Jan-03-23 04:05PM
Dec-23-22 06:36AM
Dec-16-22 10:48AM
Dec-15-22 07:00AM
Dec-09-22 09:35AM
Dec-01-22 04:05PM
07:39AM Loading…
Nov-12-22 07:39AM
Nov-10-22 04:05PM
Nov-08-22 07:15PM
Nov-07-22 08:05AM
Nov-04-22 10:00AM
Nov-02-22 04:05PM
Oct-25-22 07:59AM
Oct-17-22 12:54PM
Oct-06-22 04:05PM
Oct-05-22 08:05AM
Sep-28-22 04:05PM
Sep-15-22 09:40AM
09:55AM Loading…
Sep-12-22 09:55AM
Aug-30-22 04:05PM
Aug-26-22 09:55AM
Aug-10-22 09:55AM
Aug-08-22 06:30AM
Aug-04-22 06:25PM
Jul-17-22 09:49AM
Jun-30-22 01:08PM
Jun-17-22 07:38AM
Jun-07-22 04:05PM
May-25-22 03:00PM
May-10-22 04:05PM
May-09-22 11:29AM
May-05-22 09:31AM
May-04-22 04:05PM
May-03-22 09:55AM
May-02-22 04:30PM
Mar-29-22 04:05PM
Mar-20-22 08:02AM
Mar-16-22 06:26AM
Mar-08-22 04:45PM
Feb-17-22 04:38PM
Jan-31-22 04:05PM
Jan-24-22 12:39PM
Jan-19-22 11:11AM
Jan-15-22 08:31AM
Jan-04-22 04:05PM
Dec-16-21 04:05PM
Dec-15-21 04:05PM
Dec-02-21 04:05PM
Nov-16-21 08:49AM
Nov-12-21 08:00AM
Sep-30-21 06:01PM
Sep-17-21 10:16AM
Sep-08-21 04:05PM
Aug-12-21 04:05PM
Jul-18-21 11:39AM
Jul-01-21 02:46PM
Jun-17-21 05:29PM
Jun-16-21 09:49PM
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T-cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies, such as c-Jun overexpression and NR4A3 gene knockout, to endow resistance to T-cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi-R to generate population of T cells with durable stemness, and Stim-R, a proprietary synthetic cell mimetic. The company's pipeline includes LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T-cell product candidate for the treatment of various solid tumors; LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119, a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Klausner RichardDirectorSep 23Sale6.4011,10071,041988,900Sep 27 06:14 PM
Bishop Hans EdgarDirectorSep 08Option Exercise0.10145,38014,5384,685,614Sep 09 04:05 PM